Introduction
The Gastroesophageal Reflux Disease (GERD) represents one of the most frequent benign upper gastro intestinal condition in developed countries. It continues to increase its incidence, significantly affecting patients' quality of life being also a risk factor for Barrett's esophagus (1) .
It is caused by altering the anti-reflux barrier mechanisms, in particular the lower esophageal sphincter (LES) function and competence (2) . The initial approach of treatment consists in lifestyle changes, with or without PPI's (Proton Pump Inhibitors), although 30 to 40% of patients are refractory to optimized PPI medication (3) . PPI refractory patients, patients with severe symptoms, with atypical symptoms, regurgitation, large hiatal hernias are surgical candidates, the gold standard surgical treatment being the LNF (Laparoscopic Nissen Fundoplication), with good results at long term follow up, at expense of post fundoplication syndromes (gas bloat, dysphagia, inability to vomit and belch), in particular when performed by low volume experienced surgeons (2, 3, 4) .
Only 0.5% of GERD patients receive surgical treatment in the US, those 30-40% refractory to PPI's patients or those patients who decline surgery because of the new onset symptoms post fundoplication, represent the "treatment gap" patients (5, 6) . For well selected patient population, in the last few years, new options of minimally invasive surgical (endoscopic or laparoscopic) options are available. These new techniques are indicated for this well selected subgroup of patients, improving the LES function, without modifying the anatomy, being more efficient compared to PPI's, with less side Cuvinte cheie: BRGE recidivată, EsophyX Z, fundoplicatura endoscopică, reoperaţie, premieră mondială
Abstract
Transoral Incisionless Fundoplication (TIF) with EsophyX device for a well selected GERD patient population has proven its efficacy, safety and durability. We present a case report of a male, 63 y old, with typical and atypical GERD symptoms started 15 years ago. The esophagogastroduodenoscopy (EGD) showed a Hiatal Hernia (HH) of 3 cm and an erosive esophagitis Los Angeles Grade B. The first surgery was performed 7 years ago, in March 2009: a TIF with the EsophyX 2 ® device (EndoGastric Solution, Inc., Redmond, WA, United States). Post-surgery the symptoms were controlled, completely eliminated, the EGD showing the healing of the esophagitis. Six years after the surgery the sore throat re-appears, while the EGD shows a 2 cm hiatal hernia and erosive esophagitis Los Angeles Grade A. The Impedance pH-metry confirms GERD with a DeMeester score of 44.5. In 2016 (7 years after first procedure) a second and new TIF 2.0 procedure, this time with EsophyX Z device is performed. The EsophyX Z device is an automatic stapler-like fastener delivery system, easier of use, faster, safer and more reproducible (standardized fastener delivery). The time of the procedure was significantly reduced, compared to first procedure. The patient is now symptom free, EGD is normal, the impendance ph metry at 13 months post-surgery showed a normal DeMeester score at 8. This is a World's first case report of a TIF 2.0 procedure with EsophyX Z device 7 years after a first TIF procedure with EsophyX 2 device, with excellent results and a significant reduction of the time for the procedure.
Key words: recurrent GERD, EsophyX Z, redo transoral incisionless fundoplication (TIF 2.0), first worlide case report effects compared to LNF and technically easier to be performed (7, 8) . All endoscopic, endoluminal techniques improve and augment the LES function, either by thermal therapy (radiofrequency) or by mimicking the antireflux long term well proven fundoplications. The new laparoscopic techniques, augment the LES by implanting a magnetic ring around the distal esophagus, or a foreign body comparable to a pacemaker, with two electrodes placed at the LES, stimulating its function (8) .
Transoral Incisionless Fundoplication or TIF 2.0 with EsophyX device (Endogastric Solutions, Redmond, WA, USA) TIF 2.0 is the most known and used endoluminal technique, with more than 22,000 procedure worldwide, performing a gastroesophageal valve, recreating the angle of Hiss, reproducing the well known principles of Nissen Fundoplication (2). TIF 2.0 is performed by a single use device, being now automatic, stapler-like device, at its third iteration: EsophyX Z ( Fig. 1 
) (9).
We present a case report of a patient who received in 2009 the ELF (EndoLuminal Fundoplication), with the EsophyX2 device, which is not commercialized anymore. The patient presents with new GERD symptoms for which he received 7 years later, in 2016 the TIF 2.0 procedure with the new automatic last iteration of the EsophyX Z device, being the first Worldwide patient receiving this new last generation of procedure (TIF 2.0) with the last iteration of the device (EsophyX Z).
Case Report
The patient A.E.N., 63 year old male, has atypical symptoms of GERD since 2015, with matinal dysphonia, and chronic laryngitis. The patient presented typical GERD symptoms, since 2001. In the beginning, the patient's history describes pyrosis, and acid regurgitations with postprandial and sporadic manifestations, triggered by alcohol intake (white wine) a/o coffee. (Fig. 2) .
In March 2009 the patient receives the ELF procedure with EsophyX 2 by one of the authors (A.L.) during a surgery symposium and demonstration treating live 4 patients (10). The patient is under general anesthesia with nasotracheal intubation. The procedure takes 43 minutes with a total of 30 fasteners deployed (Fig. 3) . The patient is discharged 6 hours postoperatory getting back on routine activity 72 hours later. The diet for 4 weeks consisted of liquids (10 days), and soft food (20 days). The EGD post procedure was performed at 3 months, showing a normal physiological constructed gastro-esophageal valve. Two additional EGD's in 2011 and 2013 showed normal aspect of the GEJ. Lifestyle changes and constant physical activity improved the BMI to a total of 32 fasteners deployed (Fig. 6 ). The patient is discharged 4 hours later, on routine activity 48 hours post TIF 2.0. The diet is followed for 7 weeks, moderate physical activity for 3 weeks and PPI plus prokinetics therapy for 2 weeks. The EGD is performed at 60 days postop, showing a normal constructed GEJ/fundoplication (Fig. 7) .
At 1 year follow up, the pH impedance test shows a total percent time pH<4 in 2.4% of time (normal values defined <5%), with a total reflux episodes of 41 (normal values defined as <73). We noted that the proximal esophagus was abnormally exposed to weekly acid (28 episodes, normal values being defined as <26), which could explain a possible ENT symptoms. The DeMeester score is normal: 8.8 (Fig. 8) . The patient is with no symptoms, no treatment, normal diet and intense physical activity.
Discussions
First Worldwide EndoLuminal Fundoplications (gastro-gastric plications) were performed in Europe 2005, the procedure being cleared by the FDA in 2007. More than 22,000 procedures have been performed as by October 2018, 89 peerreviewed articles published with 1,300 unique patients treated. The quality of life is significantly improved as well as the symptom control, compared to optimized dose on PPI's. The EAE (Esophageal Acid Exposure) is significantly improved, 90% of patients have demonstrated healing of esophagitis, 71% of patients being completely off PPI's. The safety profile of the procedure is an exemplary one, with 0.41% serious Adverse Events (SAE's). We can affirm, the procedure is safer than a colonoscopy, which describes <1% SAE's (11).
In our report, the patient himself opted for the endoluminal surgery, which we took in consideration. The medical treatment was not an option, as the patient had anatomical defects, hiatal hernia associated with reflux esophagitis persistent clinical symptoms, atypical symptoms (LPR). Based on this algorithm, where the medical treatment is ineffective, we decided to go for the endoluminal surgery which is less aggressive, and with significant less adverse events compared to Laparoscopic Fundoplications (12, 13) . TIF 2.0 is performed with the EsophyX Z device, an over the endoscope device for single use, which, during a single insertion, creates a partial 270 degrees fundoplications, with a minimum of 3 cm valve length. The gastric fundus is apposed to the distal abdominal esophagus (full thickness plications), secured with 3-0 strength equivalence of polypropylene non resorbable H-shaped fasteners (9).
The TIF 2.0 received in 2017 from SAGES (Society of American Gastrointestinal Surgeons) "strong recommendation", based on a highquality level of clinical evidence +++ for well selected GERD patient population (14). This favorable strong recommendation is based on level I clinical evidence from randomized clinical trials RESPECT, TEMPO and SHAM where TIF 2.0 shows significant superiority compared to optimized PPI therapy a/o SHAM, taking in consideration and evaluating the typical and atypical symptom resolution, healing of esophagitis, significant reduction of the esophageal acid exposure and PPI treatment cessation (15, 16, 17) .
Patient selection is of major importance for optimal patient outcomes. Inclusion crieteria's: objectively confirmed GERD, patients respon- sive to PPI's, patients refractory to medication, or partial responders, atypical symptoms (extraesophageal manifestations), moderate esophagitis (Los Angeles Grade A and B), no hiatal hernia or HH < 2 cm, Hill grade I or II, normal esophageal motility, BMI<35, ASA I-III (12, 18) .
Predictive factors of success are: age > 50Y and GERD-HRQL scores at baseline on PPI's >15 (values are from 0-no symptoms to 50-severe maximum symptoms), an average of 20+ fasteners (19, 20) . In our case report, the patient was >50 years old, received 32 fasteners and was either off PPI's or occasionally on PPI's. A recent Meta-Analysis on 5 RCT's and 13 prospective studies on a total of 963 ELF/TIF 1.0/TIF 2.0 patients showed significant improvement of typical and atypical symptoms, reduction of total % time of EAE and significant reduction of reflux episodes. The satisfaction rate at six months was 69,15%, as there were included different iterations of the procedure which today are not performed anymore: ELF and TIF 1.0. The long-time follow-up shows a reduction in efficacy in time although on a side note, one RCT (Witteman) violated inclusion criteria's, including patients with large hiatal hernias and Hill Grade III and IV which represent a contraindication for TIF 2.0 procedures (21) .
In our case report, clinical symptoms of GERD after ELF re-appeared at 6Y after the initial ELF. Also, the HH was 3 cm at initial baseline in 2009, or we know today that the maximum HH for the obtaining the best clinical outcomes and inclusion criteria's are patients with hiatal hernia's no larger than 2 cm. Only 2 fasteners were still identified at the EGD control in 2016. The acid reflux was important with a DeMeester score of 44. But, there were no typical symptoms. The long-term data on TIF 2.0 has been reported in 2 peer reviewed articles/studies. At 5Y TEMPO Randomized Clinical Trial follow up, 90% of patients had no more GERD typical or atypical symptoms, the esophagitis healed in 86%, GERD-HLQR mean scores were 5, all esophageal pH parameters improved, 71% of patients completely stopped PPI therapy (22) . Fourteen patients were followed up long term, at 6Y post TIF 2.0 with 85,75% off daily PPI's (20) .
In our report, the GERD atypical symptoms re-appeared at more the 6Y from the initial FEE. This could be explained by a 3 cm Hiatal Hernia in 2009, with recurrence at 2 cm in 2015, with new onset esophagitis, important acid reflux with a DeMeester Score at 44, all this without any typical symptoms. Again, we opted for the endoscopic approach, based on the same considerations presented above.
The new EsophyX Z device cleared by the FDA in May 2016 has multiple advantages (compared with the EsophyX2 which is not manufactured anymore by the Company): easier to use, faster procedure time, the fasteners are deployed by automatically activating the trigger, similarly with surgical stapler mechanisms, more efficient, dual fastener deployment, safer for the patients (as stylets are protected), reduced crossing profile (23). Also, the anesthesia is shorter and requires standardized orotracheal intubation, easier to perform than naso-tracheal intubation for ELF and TIF 1.0 procedures with EsophyX 2 device, no more offered nor device manufactured. The time of the procedure is significantly reduced (in our report from 43 minutes to 22 minutes), the procedure having been performed by the same experienced surgeon (A.L.). The patient is today, 2Y post-procedure symptom-free, EGD is normal, weekly acid reflux with a normal DeMeester score of 8. TIF 2.0 procedure can be easily re-done, can be performed on failed Nissens (if diaphragmatic defect is less than 2 cm) and also, TIF 2.0 does not burn any bridges, as a second TIF 2.0 procedure or a LNF can be easily performed on patients post TIF (24, 25) . If hiatal hernias are larger than 2 cm, with recent FDA clearance which approved TIF procedure if the hiatal hernia is repaired and reduced below 2 cm in size, Chang et al., described the concomitant (or hybrid) procedures. The advantage being no post fundoplication new onset symptoms such as dysphagia or gas bloat: laparoscopic approach with or without HH repair with biologic mesh reinforcement followed by a TIF 2.0 in selected patients (26). TIF 2.0 being the most successful endo-scopic fundoplication, is effective for patients refractory to PPI's. The development of different iterations of devices and techniques was in accordance with obtaining similar effective outcomes proved by the laparoscopic Nissen gold standard procedure. Research are in present conducted which demonstrates long term durability of TIF 2.0 procedure. The longest follow up for the TIF 2.0 procedure was reported at 10 years by Testoni et al (27) .
Conclusion
In conclusion, our case presented has some specifics. The patient is a surgeon with experience in LNF, and one of the authors. We describe the World's first reoperation with "EsophyX Z" with good results at 1Y follow up.
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